

30 January 2026

## Myasthenia Gravis Treatments

I would like to submit an FOI request to Belfast Health and Social Care Trust for the following information:

The number of patients with myasthenia gravis [ICD-10 Code G70.0] treated with the following in each month for July, August, September, October, November and December 2025:

Anti-CD20 (Rituximab)  
Anti-FcRn (efgartigimod, rozanolixizumab)  
Complement Inhibitors (eculizumab, ravulizumab, zilucoplan)  
Plasma Exchange

Belfast Trust is unable to provide the information requested, i.e. number of patients treated with the above during July to December 2025, as this information is not held.

We can provide information on patients who were admitted / discharged with the diagnosis of myasthenia gravis [ICD-10 Code G70.0] but we would not be able to confirm the numbers treated with these specific treatments.

### Immunoglobulins

Answer for number of Myasthenia Gravis patients treated with Immunoglobulin in each of the specified months:

July 2025	<5 patients
August 2025	<5 patients
September 2025	<5 patients
October 2025	<5 patients
November 2025	<5 patients
December 2025	<5 patients

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.